Biosense Webster: Heart Ablation Devices

2023: Product Announcement

On August 4, 2023, the company, Biosense Webster a subsidiary of Johnson & Johnson MedTech, announced the release of a number of devices for ablation hearts without fluoroscopy. We are talking about products intended for the treatment of atrial fibrillation - arrhythmias this is one of the most common forms of heart rhythm disorder.

Fluoroscopy is a medical imaging technique in which an X-ray image is continuously displayed on a monitor. This approach is used both in various examinations and in the course of therapy. However, the use of fluoroscopy can lead to relatively high doses of radiation - especially in complex interventional procedures. Biosense Webster's new products reduce radiation load, which in the long term can minimize the risk of developing malignancies.

Biosense Webster Thermocool Smarttouch SF

Cardiac ablation procedures for the treatment of atrial fibrillation (atrial fibrillation) usually require fluoroscopy to control the advancement and positioning of intracardiac catheters, resulting in significant exposure of patients, operators, and support medical staff. In addition, it creates a high orthopedic load from protective clothing, in particular, from lead aprons, "said Jose Osorio, MD, president of Heart Rhythm Clinical and Research Solutions.

For cardiac ablation without fluoroscopy, Biosense Webster products such as Thermocool Smarttouch SF catheters, Thermocool Smarttouch and Pentaray Nav Eco, Carto Vizigo Bi-Directional Guiding Sheath bidirectional introducer, and Decanav family catheters and Webster CS catheter can be used. Ultrasound can be used as an alternative to fluoroscopy when using these tools.^[1]

Notes